NASDAQ:NBSE
Neubase Therapeutics Inc Stock News
$0.378
+0 (+0%)
At Close: May 17, 2024
The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance
12:02pm, Friday, 27'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.None of the NYSE- or Nasdaq-listed biotech stocks hit 52 week highs Thursday.Down In The Dumps (Biotech Stocks Hitting
Slight gains for the week do little to restore area stock prices
06:23pm, Thursday, 26'th Mar 2020
The stock market ticked up for local companies, but the COVID-19 crisis has still taken its toll.
Chardan Capital Keeps Their Buy Rating on NeuBase Therapeutics (NBSE)
03:27am, Friday, 20'th Mar 2020
Chardan Capital analyst Keay Nakae reiterated a Buy rating on NeuBase Therapeutics (NBSE – Research Report) yesterday and set a
Which local stocks were hit worst by COVID-19 scare
07:59pm, Friday, 06'th Mar 2020
A look at the local public companies' stock results this week.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exelixis (
EXEL
–
Research Report
), NeuBase Therapeutics (
NBSE
–
Research Report
) and Theravance
Tracking David Einhorn's Portfolio - Q4 2019 Update
01:53pm, Wednesday, 19'th Feb 2020
David Einhorn's 13F stock portfolio value decreased from $1.39B to $1.35B this quarter. Greenlight added DXC Technology while dropping Dillard’s and Voya Financ
Allergan Reports Q4 Earnings Beat
12:00am, Monday, 10'th Feb 2020
Allergan plc (NYSE: AGN) reported quarterly earnings of $5.22 per share on Monday, beating the analyst consensus estimate of $4.57 by 14.22%.
This is a 21.68% increase over...
Baird likes drug wholesalers in premarket analyst action
12:58pm, Friday, 07'th Feb 2020
Arcturus Therapeutics (NASDAQ:ARCT) initiated with Buy rating and $19 (70% upside) price target at Guggenheim.BeyondSpring (NASDAQ:BYSI) initiated with Buy rating and $25 (45% upside) price target at
NeuBase Therapeutics Wins The Scientist’s Top 10 Innovations of 2019 Award for its Janus Base Technology
01:00pm, Monday, 02'nd Dec 2019
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that
NeuBase Therapeutics to Present at Upcoming Investor Conferences in December
01:00pm, Monday, 25'th Nov 2019
Evercore ISI HealthCONx Conference panel discussion at 12:30 p.m. ET on December 3rd Piper Jaffray 31st Annual Healthcare Conference presentation at 8:30 a.m. ET on December 4th.
NeuBase Therapeutics, Inc. (NBSE): Hedge Funds Dropped The Ball?
09:30pm, Sunday, 24'th Nov 2019
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 752 13F
NeuBase Therapeutics to Present at the Stifel 2019 Healthcare Conference
02:16pm, Tuesday, 12'th Nov 2019
PITTSBURGH, Nov. 12, 2019 -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to.
Other Barks & Bites, Friday, November 8
06:15pm, Friday, 08'th Nov 2019
his week in Other Barks & Bites: the Trump Administration sues Gilead for infringement over HIVE PrEP treatment patents; Senators Inhofe and Wicker ask President Trump to show no leniency on Chinese I
NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the Key Building Blocks of PATrOL™ Enabled Therapies
12:00pm, Thursday, 17'th Oct 2019
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the
